Personality and quality-of-life improvement after apomorphine infusion in Parkinson's disease.

Temperament and Character Inventory precision medicine therapeutics

Journal

Brain communications
ISSN: 2632-1297
Titre abrégé: Brain Commun
Pays: England
ID NLM: 101755125

Informations de publication

Date de publication:
2024
Historique:
received: 11 12 2023
revised: 17 04 2024
accepted: 24 05 2024
medline: 7 6 2024
pubmed: 7 6 2024
entrez: 7 6 2024
Statut: epublish

Résumé

People with Parkinson's disease with motor fluctuations can be treated by continuous subcutaneous apomorphine infusion (CSAI) to reduce their symptoms. Nonetheless, factors are lacking to predict patients' quality-of-life amelioration after CSAI. This pilot study aimed to evaluate associations between personality dimensions and quality-of-life improvement after 6 months of CSAI. Thirty-nine people with Parkinson's disease awaiting CSAI were included. Linear regression models between 'Temperament and Character Inventory' personality dimensions at baseline and percentage of change in Parkinson's Disease Questionnaire-39 scores after 6 months of CSAI were realized (

Identifiants

DOI: 10.1093/braincomms/fcae181 PMID: 38846534 PMC: PMC11154139
pubmed: 38846534
doi: 10.1093/braincomms/fcae181
pii: fcae181
pmc: PMC11154139
doi:

Types de publication

Journal Article

Langues

eng

Pagination

fcae181

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the Guarantors of Brain.

Déclaration de conflit d'intérêts

The authors report no competing interests.

Auteurs

Mathilde Boussac (M)

Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, 31024 Toulouse, France.
ORCID: 0000-0002-3532-6743

Estelle Harroch (E)

Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Clinical Investigation Center, University Hospital of Toulouse, NeuroToul COEN (Center of Excellence in Neurodegeneration), 31024 Toulouse, NS-PARK/FCRIN Network, France.

Christel Barthelemy (C)

Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Clinical Investigation Center, University Hospital of Toulouse, NeuroToul COEN (Center of Excellence in Neurodegeneration), 31024 Toulouse, NS-PARK/FCRIN Network, France.

Fabienne Ory-Magne (F)

Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, 31024 Toulouse, France.
Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Clinical Investigation Center, University Hospital of Toulouse, NeuroToul COEN (Center of Excellence in Neurodegeneration), 31024 Toulouse, NS-PARK/FCRIN Network, France.

Clémence Leung (C)

Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Clinical Investigation Center, University Hospital of Toulouse, NeuroToul COEN (Center of Excellence in Neurodegeneration), 31024 Toulouse, NS-PARK/FCRIN Network, France.

Margherita Fabbri (M)

Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, 31024 Toulouse, France.
Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Clinical Investigation Center, University Hospital of Toulouse, NeuroToul COEN (Center of Excellence in Neurodegeneration), 31024 Toulouse, NS-PARK/FCRIN Network, France.

Christophe Arbus (C)

Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, 31024 Toulouse, France.
Psychiatry Department of the University Hospital of Toulouse, CHU Purpan, 31024 Toulouse, France.

Christine Brefel-Courbon (C)

Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, 31024 Toulouse, France.
Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Clinical Investigation Center, University Hospital of Toulouse, NeuroToul COEN (Center of Excellence in Neurodegeneration), 31024 Toulouse, NS-PARK/FCRIN Network, France.

Classifications MeSH